Breaks Categories: News

ThursdayMay 14, 2020 11:14 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin*. Extremely versatile, the NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus.…

Continue Reading

ThursdayMay 07, 2020 11:10 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces At-The-Market Priced $2.2M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock. According to the update, the shares are each $1.575, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $2.2 million. In addition, Predictive Oncology has agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. Subject to…

Continue Reading

WednesdayMay 06, 2020 11:55 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According to the update, the groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein), which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things. NIH is currently exploiting the…

Continue Reading

TuesdayMay 05, 2020 10:26 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Expands Oncology Franchise via Exclusive Worldwide Patent and Technology License Agreement

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it has entered into a patent and technology license agreement with The University of Texas MD Anderson Cancer Center, granting Genprex an exclusive worldwide license to a portfolio of 16 patent applications and related technology (“Licensed IP”) for the treatment of cancer using Genprex’s lead drug candidate and TUSC2 gene therapy, known as “Oncoprex” or “GEN-001,” in combination with immunotherapies. The Licensed IP covers the use of Oncoprex in combination with one or more immunotherapies for the treatment of…

Continue Reading

MondayMay 04, 2020 2:20 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Shareholder Letter Highlighting Oncoprex(TM) Progress, License Agreement for a Diabetes Drug Candidate and Other Achievements

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its issuance of an April 2020 Shareholder Letter. According to the update, the letter highlights the Company’s progress with Oncoprex(TM), its lead drug candidate with an initial targeted indication for non-small cell lung cancer (“NSCLC”), its license agreement for a diabetes gene therapy drug candidate, as well as other operational and business achievements. A digital copy of the letter can be found on the Company’s website. To view the full press release, visit http://nnw.fm/bm9L2 About Genprex, Inc. Genprex, Inc. is…

Continue Reading

ThursdayApr 23, 2020 9:21 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Executes Agreement to Exchange $2.1M Debt for Equity

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Wednesday announced that it has entered into an exchange agreement with POAI chief executive officer Dr. Carl Schwartz regarding a $2.1 million promissory note of the company. Per the agreement, Dr. Schwartz has exchanged the note for 1,533,481 shares of newly issued common stock at an exchange rate of $1.43 each, the closing price of the common stock on April 21, 2020. Dr. Schwartz agreed to not sell or transfer 766,740 shares (one-half of the shares) for three months after…

Continue Reading

WednesdayApr 22, 2020 11:15 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO Discusses Distinctive Business Model in Exclusive Interview

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its director and CEO Dr. Carl Schwartz was featured in an exclusive interview with BioMedWire (“BMW”). In the interview, Dr. Schwartz discussed Predictive Oncology’s distinctive business model, as well as significant changes management is making to position the company for the future. “Predictive’s major asset is its Helomics subsidiary and its proprietary database of over 150,000 cancer tumors covering over 137 types of cancers, with over 30,000 tumors related to ovarian cancer, which is sort of our specialty.…

Continue Reading

TuesdayApr 21, 2020 10:43 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Accomplished Executive Shannon Inman to Drive Launch of Key Clinical Trials

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced the appointment of Shannon Inman as Vice President of Global Clinical Operations. According to the update, Inman will lead in defining clinical developmental strategies, clinical protocol design, study conduct, and managing risk assessment in this new position. These clinical trials include those with Genprex’s lead drug candidate, Oncoprex(TM), for non-small cell lung cancer (“NSCLC”), which recently received Fast Track Designation for its combination with osimertinib, AstraZeneca’s first-line targeted EGFR TKI drug Tagrisso(R). “Genprex continues to strengthen its leadership team with…

Continue Reading

WednesdayApr 01, 2020 10:59 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Full-Year 2019

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today released financial results for its full year ended December 31, 2019, as well as select corporate highlights. Among the highlights, the company reported its securing of a $15.0 million equity line with Oasis Capital, LLC, as well as its new subsidiary, Helomics, reaching milestone sequencing tumor cases in partnership with UPMC Magee. “2019 was not without its challenges for the entire healthcare technology industry, yet we continued to execute on our business model, making a synergistic acquisition and shoring up…

Continue Reading

TuesdayMar 31, 2020 12:05 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Helomics’ Continued Progress Toward Developing AI-Driven Predictive Model of Ovarian Cancer

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress by its Helomics subsidiary toward the goal of developing an AI-driven predictive model of ovarian cancer (CancerQuest 2020). Per the update, CancerQuest2020 (CCQ2020) is focused on building an AI-driven model of ovarian cancer that will predict drug response and outcome. Predictive models embody the knowledge from these profiles, creating a “computational expert” or a “virtual patient” that can be queried. “Despite some headwinds imposed by the current COVID-19 pandemic, the Helomics team has been working diligently to…

Continue Reading